PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer.

Journal:

Journal of Clinical Oncology

Published:

2025-09-11

DOI:

10.1200/jco-25-00436

Affiliations:

12

Authors:

36

Go to article

Institutions	Authors	Share
Princess Margaret Cancer Centre, U of T, Canada	15.000000 15.000000	0.42
Ontario Institute for Cancer Research (OICR), Canada	5.000000	0.14
Dana-Farber Cancer Institute (DFCI), United States of America (USA)	4.000000	0.11
Northwell Health, United States of America (USA)	3.000000	0.08
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, United States of America (USA)	2.500000	0.07
Lustgarten Foundation Pancreatic Cancer Research Laboratory, United States of America (USA)	1.500000	0.04
Cold Spring Harbor Laboratory (CSHL), United States of America (USA)	1.500000	0.04
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA)	1.000000	0.03
Weill Cornell Medicine, United States of America (USA)	1.000000	0.03
BC Cancer Agency (BCCA), PHSA, Canada	1.000000	0.03
Sibley Memorial Hospital, JHU, United States of America (USA)	0.500000	0.01

Interested in Oncology and Carcinogenesis?